Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
GORTEC 2014-04 trial: what clinicians have said so far
Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC
- NCT03070366 ↗
- Active, not recruiting
- Groupe Oncologie Radiotherapie Tete et Cou
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on GORTEC 2014-04 (head and neck squamous cell carcinoma with oligometastases; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on GORTEC 2014-04 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X | |
| 1 podcast episode |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Trial Comparing Chemotherapy Combined With Stereotactic Radiotherapy and Stereotactic Radiotherapy Alone, for Treatment of Oligometastases in Squamous Cell Cancers of the Upper Aerodigestive Tract
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Chemotherapy; Stereotactic radiotherapy
- Arms
- Chemotherapy combined with stereotactic radiotherapy (RT) · Active comparator
- stereotactic radiotherapy · Experimental
- Enrollment
- 78 (estimated)
- Primary outcomes
- Overall Survival without quality of life deterioration
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
- Start
- Sep 21, 2015
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03070366 · updated Oct 2, 2026